Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

NCT04701307 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lung Small Cell Carcinoma
Neuroendocrine Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8

Interventions

BIOLOGICAL: Dostarlimab
DRUG: Niraparib

Sponsor

M.D. Anderson Cancer Center